Achilles Therapeutics PLC at JPMorgan Healthcare Conference Transcript
Good morning. I'm Eric Joseph, senior biotech analyst with J.P. Morgan. And our next presenting company is Achilles Therapeutics. And presenting on behalf of the company is CEO, Iraj Ali. (Conference Instructions)
So with that, Iraj?
Thanks, Eric. Wonderful to have this opportunity to tell you a little bit more about Achilles Therapeutics' progress and plans to date. So I draw your attention to the forward-looking statements and disclaimers to review in your own time.
So Achilles is a clinical stage oncology business, developing multiple programs in using a T cell therapy to address late-stage metastatic disease. We are targeting a novel class of antigen, the clonal neoantigen that we believe can unlock transformational efficacy. And we believe that we can show here today the beginnings of the concept of going from tumor genetics to target engagement, and that can be designed and demonstrated through to the patient.
The company was founded in early 2016
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
